BrightInsight names biopharmaceutical and digital health expert Brad Gescheider to Advisory Council

Brad advisory blog

We are excited to announce the appointment of Brad Gescheider to the BrightInsight Advisory Council. His experience rounds out this group of industry experts, who work with BrightInsight leadership to advance the company’s vision to transform patient outcomes globally through the power of digital technology.

We are delighted to have Brad join our Advisory Council, providing insights based on his experience with innovating digital therapeutics, health tech and patient care models. Our team and client partners will benefit from his guidance as we continue growing current and new markets and expanding our portfolio of digital health solutions.

Brad joins the advisory council as we continue solidifying our position as the de facto digital health platform for medtech and biopharma. To date in 2022, we announced new biopharma partnerships for digital health solutions with bioMérieux and Sanofi joining its list of customers that includes CSL Behring, Roche, Novo Nordisk and others. We also recently launched the BrightInsight Ecosystem for partner collaboration to advance digital health, the BrightInsight Connected Diagnostics Platform for in vitro diagnostics and its Digital Disease Management Solution.

"Software as a Medical Device (SaMD) offers tremendous potential to advance patient care," said Brad Gescheider, Chief Commercial Officer, Woebot Health. "Through its compliant platform, BrightInsight is reducing the challenges many life sciences companies face in bringing regulated digital health solutions to market to drive value for their therapies. I’m excited to join the BrightInsight Advisory Council and help the team advance the industry’s adoption of digital solutions."

Brad recently joined Woebot Health to lead initiatives that align with its mission to create new ways to deliver mental health care. Previously, he served as Vice President & Global Head of Digital Innovation & Patient Services, Immunology for Sanofi, and earlier in his career was Vice President of Business Development and Market Intelligence with Constant Therapy Health. Brad has also been an Advisory Council Member for the Office of the National Coordinator for Health Information Technology (ONC) and Blue Cross Blue Shield Association.

Brad joins some of the world’s most accomplished healthcare, technology and business thought leaders including Mark T. Bertolini, Karl Hick, Tamara Elias, MD, Scott Huennekens, Stephen Oesterle, MD, Donald Jones, Jeffrey Leiden, M.D., Ph.D., Diana McKenzie, Kim Powell, Brent Saunders, Meinhard F. Schmidt, Jagjot (JJ) Singh, Bradley Stock, Elisabethann Wright and Hemant Taneja.

Back to Blog